Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 637

1.
2.

Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.

Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, et al.

Ann Intern Med. 1991 Aug 15;115(4):256-65.

PMID:
1906692
5.

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, et al.

Circulation. 1987 Jul;76(1):142-54.

PMID:
3109764
6.
7.

Thrombolysis in myocardial infarction (TIMI): update 1987.

Mueller HS.

Klin Wochenschr. 1988;66 Suppl 12:93-101.

PMID:
3126350
9.

Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?

Collen D.

Ann Intern Med. 1990 Apr 1;112(7):529-38. Review.

PMID:
2107781
10.

Late activation of the fibrinolytic system in myocardial infarction treated with thrombolytic therapy. Influence of the coronary anatomical substrate.

Salvioni A, Perego GB, Marenzi G, Lauri G, Giraldi F, Grazi S, Guazzi MD.

Eur Heart J. 1996 Feb;17(2):230-6.

PMID:
8732376
11.

A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.

Grines CL, Nissen SE, Booth DC, Gurley JC, Chelliah N, Wolf R, Blankenship J, Branco MC, Bennett K, DeMaria AN.

Circulation. 1991 Aug;84(2):540-9.

PMID:
1907228
12.
13.

Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.

Sane DC, Stump DC, Topol EJ, Sigmon KN, Clair WK, Kereiakes DJ, George BS, Stoddard MF, Bates ER, Stack RS, et al.

Circulation. 1991 Jan;83(1):170-5.

PMID:
1898641
14.

Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.

Anderson JL, Rothbard RL, Hackworthy RA, Sorensen SG, Fitzpatrick PG, Dahl CF, Hagan AD, Browne KF, Symkoviak GP, Menlove RL, et al.

J Am Coll Cardiol. 1988 Jun;11(6):1153-63.

16.

A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.

Koster RW, van Stralen R, McNeill AJ, Adgey AA, Fox KA, Dymond D, Sponzilli C, Jewitt D, Bucknall C, Kluft C, et al.

Eur Heart J. 1990 Aug;11(8):730-9.

PMID:
2118853
17.
18.

Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.

Williams DO, Borer J, Braunwald E, Chesebro JH, Cohen LS, Dalen J, Dodge HT, Francis CK, Knatterud G, Ludbrook P, et al.

Circulation. 1986 Feb;73(2):338-46.

PMID:
3080261
19.
20.

Supplemental Content

Support Center